Moderna hits primary endpoint in Covid vax trial for youngest kids, but efficacy tops out at under 45%
Moderna on Wednesday said it’s headed to the FDA for an emergency authorization for its vaccine in the youngest group of children (under 6) with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
